Recent Investment Analysts’ Ratings Changes for Medexus Pharmaceuticals (MDP)

Medexus Pharmaceuticals (TSE: MDP) has recently received a number of price target changes and ratings updates:

• 2/7/2025 – Medexus Pharmaceuticals was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating. They now have a C$3.45 price target on the stock, down previously from C$6.00.
• 2/6/2025 – Medexus Pharmaceuticals was downgraded by analysts at Stifel Canada from a “strong-buy” rating to a “hold” rating.
• 1/30/2025 – Medexus Pharmaceuticals had its price target raised by analysts at Ventum Financial from C$5.00 to C$6.25. They now have a “buy” rating on the stock.
• 1/30/2025 – Medexus Pharmaceuticals had its price target raised by analysts at Stifel Nicolaus from C$4.50 to C$6.00.
• 1/22/2025 – Medexus Pharmaceuticals was upgraded by analysts at Leede Financial from a “moderate buy” rating to a “strong-buy” rating.
• 1/17/2025 – Medexus Pharmaceuticals was upgraded by analysts at Ventum Cap Mkts to a “strong-buy” rating.
• 1/14/2025 – Medexus Pharmaceuticals had its price target raised by analysts at Stifel Nicolaus from C$4.15 to C$4.50.
• 1/8/2025 – Medexus Pharmaceuticals was upgraded by analysts at Raymond James from an “outperform” rating to a “strong-buy” rating. They now have a C$4.00 price target on the stock.
• 12/23/2024 – Medexus Pharmaceuticals was upgraded by analysts at Alliance Global Partners to a “strong-buy” rating.

Medexus Pharmaceuticals Trading Down 1.6 %

MDP opened at C$3.09 on Monday. Medexus Pharmaceuticals Inc. has a 1-year low of C$1.47 and a 1-year high of C$5.56. The company has a market cap of C$69.18 million, a P/E ratio of 14.78 and a beta of 1.96. The company has a fifty day moving average price of C$3.57 and a two-hundred day moving average price of C$2.86.

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.